Investigating how Checkpoint kinase 2 affects immune response in gliomas
The immunosuppressive function of Checkpoint kinase 2 in gliomas
This study is looking at how glioma tumors manage to hide from the immune system and whether blocking a specific protein called Chek2 can help make current treatments work better for patients with these tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10944895 on NIH RePORTER |
What this research studies
This research focuses on understanding how glioma tumors evade the immune system, particularly the role of Checkpoint kinase 2 (Chek2) in this process. By using advanced techniques like CRISPR screening, the researchers aim to identify how Chek2 contributes to the tumor's ability to resist being attacked by CD8 T cells, a type of immune cell. The study will explore the interactions between Chek2 and specific proteins that regulate immune responses, and it will test whether inhibiting Chek2 can enhance the effectiveness of existing immunotherapies. This could lead to new treatment strategies for patients with gliomas.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with gliomas, particularly those who have not responded well to current treatments.
Not a fit: Patients with gliomas who are not eligible for immunotherapy or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for patients with gliomas, potentially enhancing their survival rates.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in gliomas, indicating potential for success with this approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Dmello, Crismita Clement — Northwestern University at Chicago
- Study coordinator: Dmello, Crismita Clement
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.